FibroBiologics (FBLG) vs Lexaria Bioscience (LEXX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
FibroBiologics is the larger company by market cap ($8.1 million vs $6.7 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FBLG | LEXX |
|---|---|---|
| Share price | $1.16 | $3.20 |
| Market cap | $8.07M | $6.74M |
| 1-day change | +4.50% | -4.76% |
| EPS (TTM) | $-5.01 | $-5.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.98 | $21.60 |
| 52-week low | $0.62 | $2.77 |
| Distance from 52-week high | -88.38% | -85.19% |
| Analyst consensus | none | none |
| Avg. price target upside | +977.59% | +2478.12% |
| Average volume | 204.44K | 62.36K |
| Shares outstanding | 6.96M | 2.11M |
| Employees | 15 | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About FibroBiologics
FBLG stock →FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
About Lexaria Bioscience
LEXX stock →Lexaria Bioscience Corp. operates as a biotechnology company.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
FBLG vs LEXX FAQ
Which is bigger, FibroBiologics or Lexaria Bioscience?
FibroBiologics (FBLG) is larger, with a market capitalization of $8.07M compared with $6.74M for Lexaria Bioscience (LEXX).
Are FibroBiologics and Lexaria Bioscience in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.